GeneThera, Inc. Retains Pfeiffer High Investor Relations

ARVADA, CO--(Marketwire - July 23, 2009) - GeneThera, Inc. (PINKSHEETS: GTHR) today announced it has retained Pfeiffer High Investor Relations, Inc. to develop and implement a comprehensive investor relations program.

Dr. Tony Milici, founder and CEO of GeneThera, said, "We are nearing the achievement of multiple strategic milestones, including the launch of a pivotal marketing trial for our Johne's disease testing application. It is imperative that our story and accomplishments are effectively communicated by an organization equipped to address the many facets of a successful investor relations program. We are confident we have found that organization in Pfeiffer High."

Geoff High, principal of Pfeiffer High Investor Relations, said, "GeneThera's focus on the development of testing and prevention applications for animal-to-human 'crossover' diseases could have substantial long-term implications for the global food and agricultural industries. We look forward to helping GeneThera broadly expand its audience and will work to communicate its story to retail and institutional investors, as well as the financial media."

About GeneThera, Inc.

GeneThera, Inc. is a biotechnology company focused on the development of molecular assays. The Company is currently in the process of developing therapeutic vaccines for the detection and prevention of food contaminating pathogens, veterinary diseases, and diseases affecting human health. More information about the Company can be found at: http://www.genethera.net.

About Pfeiffer High Investor Relations, Inc.

Pfeiffer High is a full-service investor relations firm based in Denver. Since 1982 it has been helping public companies maximize shareholder value by implementing comprehensive investor relations programs that raise awareness among buy- and sell-side analysts, institutional portfolio managers, brokers, individual investors and the financial media.

Safe Harbor Statement

Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Federal Private Securities Litigation Reform Act of 1995, including statements regarding our forthcoming achievement of multiple strategic milestones, the launch of a pivotal marketing trial for our Johne's disease testing applications, the potential that our focus on the testing and prevention of animal-to-human "crossover" diseases could have substantial long-term implications for the global food and agricultural industries and Pfeiffer High Investor Relations' ability to effectively communicate our story and progress to retail and institutional investors, as well as the financial media. Forward-looking statements involve known and unknown risks and uncertainties, which may cause the Company's actual results in future periods to differ materially from forecasted results. Factors that could cause or contribute to such differences include, but are not limited to, our ability to raise capital, our ability to execute our business strategy in a very competitive environment, our degree of financial leverage, risks relating to rapidly developing technology, regulatory considerations, risks related to international economies, risks related to market acceptance and demand for our products and services, the impact of competitive services and pricing, and other risks referenced from time to time in our SEC filings. All subsequent written and oral forward-looking statements attributable to us, or anyone acting on our behalf, are expressly qualified in their entirety by these cautionary statements. We do not undertake any obligations to publicly release any revisions to any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect unanticipated events that may occur.